SCHEMBL5026871

SCHEMBL5026871

Cc1cc(N2CCCC2)c2ccc(NCc3ccc(Cl)cc3)cc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
NCF1 P14598 3/20 0.49
CTNNB1 P35222 2/20 0.49
TCF7L2 Q9NQB0 2/20 0.49
GFER P55789 1/20 0.46
HTT P42858 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 2/20 0.43
USP2 O75604 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5024554 0.91 NCF1 (0.51) NPC1RAB9ANCF1CTNNB1TCF7L2
SCHEMBL6709246 0.89 MRGPRX1 (0.47) NPC1RAB9ANCF1CTNNB1TCF7L2
SCHEMBL5024388 0.89 CTNNB1 (0.49) NCF1CTNNB1TCF7L2MEN1KMT2A
SCHEMBL5028716 0.88 NCF1 (0.50) NPC1RAB9ANCF1CTNNB1TCF7L2
SCHEMBL5024595 0.87 RAB9A (0.54) NPC1RAB9ANCF1SMN1; SMN2LMNA
SCHEMBL5022553 0.86 NCF1 (0.51) NPC1RAB9ANCF1CTNNB1TCF7L2
SCHEMBL5026876 0.86 NCF1 (0.46) NCF1CTNNB1TCF7L2MEN1KMT2A
SCHEMBL5024451 0.86 NCF1 (0.46) NPC1RAB9ANCF1HTTSMN1; SMN2
SCHEMBL5028710 0.85 NCF1 (0.48) NCF1CTNNB1TCF7L2HTTMEN1
SCHEMBL5022538 0.83 NCF1 (0.53) NPC1RAB9ANCF1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474145-B1 QUINOLINE DERIVATIVES AS NPY ANTAGONISTS HOFFMANN LA ROCHE (CH) 2008-04-23 EP disclosed
CN-1627945-A Quinoline derivatives as NPY antagonists HOFFMANN LA ROCHE (CH) 2005-06-15 CN disclosed
EP-1474145-A1 QUINOLINE DERIVATIVES AS NPY ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-10 EP disclosed
US-6696467-B2 Quinoline derivatives HOFFMANN-LA ROCHE INC. 2004-02-24 US disclosed
WO-2003066055-A1 QUINOLINE DERIVATIVES AS NPY ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 WO disclosed
US-20030153553-A1 Quinoline derivatives F. HOFFMANN-LA ROCHE AG (CH) 2003-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153553-A1 Quinoline derivatives NPY1R, NPY4R, GLP1R NPC1 172/4885RAB9A 1050/4885NCF1 1858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.